Investor Type | Firm |
Industries | Education • BioTech • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Pharmaceutical (& Medicine) |
Stages | Early, Seed, Series A, Series B |
Investing | United States • France |
Investment Range | $100,000 - $5,000,000 |
Investment Sweet Spot | $1,500,000 |
T1D Fund is a venture capital investment fund initiated by JDRF, dedicated to accelerating life-changing solutions for type 1 diabetes (T1D) through strategic investments. They focus on catalyzing the development and delivery of commercial T1D therapies, devices, and platforms by investing in companies within various sectors, such as Education, BioTech, HealthTech & Fitness, Medical Devices & Hospital Services, Healthcare & Wellness, and Pharmaceutical & Medicine. With an investment range between $100,000 and $5,000,000, their 'sweet spot' for investments typically centers around $1,500,000. They specialize in early-stage funding, including Seed, Series A, and Series B rounds. T1D Fund aims to demonstrate to donors, as well as venture, corporate, and foundation capital sources, that the T1D domain offers high-impact investment opportunities. Their approach is to leverage their industry knowledge and expertise to support the growth of promising companies that are working towards breakthroughs in the T1D space. They act as a bridge between philanthropy and venture capital, seeking to align the incentives of both worlds to foster innovations that can bring about significant improvements for individuals living with T1D. The fund’s overarching goal is to drive progress in treatment options and, ultimately, cure type 1 diabetes, while seeking a return on investment for their stakeholders, which can be reinvested in furthering JDRF's mission.